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Abstract Whether an element of routine housekeeping or
in the setting of imminent disaster, it is a good idea to get
one’s affairs in order. Autophagy, the process of recycling
organelles and protein aggregates, is a basal homeostatic
process and an evolutionarily conserved response to star-
vation and other forms of metabolic stress. Our under-
standing of the role of autophagy in the heart is changing
rapidly as new information becomes available. This review
examines the role of autophagy in the heart in the setting of
cardioprotection, hypertrophy, and heart failure. Contra-
dictory findings are reconciled in light of recent develop-
ments. The preponderance of evidence favors a beneficial
role for autophagy in the heart under most conditions.
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Introduction
It is becoming increasingly apparent that autophagy and
mitophagy play an important role in modulating the cell’s
response to stress in a number of organs including brain,
liver, skeletal muscle, pancreas, and heart. This review will
focus on cardiac autophagy; the purpose is to summarize
the role of autophagy in homeostasis and pathophysiology
in the adult heart, and where possible, reconcile the studies
that suggest cardiac autophagy is a maladaptive process as
opposed to an adaptive one. In addition to cardioprotection
in the setting of ischemia–reperfusion, we will also
examine autophagy and mitophagy with a particular
emphasis on cardiac hypertrophy and heart failure.
Autophagy, mitophagy, and cardioprotection
Autophagy is the cell-autonomous process of bulk recycling
of protein aggregates; mitophagy is the specialized form of
autophagy responsible for elimination of mitochondria.
Early studies of cardiac autophagy noted that mitochondria
were frequently contained within autophagosomes, but the
significance of this was not established until much later.
Studies of ischemia/reperfusion injury revealed that reactive
oxygen species (ROS) and mitochondria were a critical tar-
get of injury, as catastrophic opening of the mitochondrial
permeability transition pore (mPTP) commonly culminated
in cell death. Many studies showed that preventing pore
opening reduced infarct size, reinforcing the notion that
mitochondrial injury was a critical event. Studies of mito-
chondria in isolated cardiomyocytes led to the recognition of
ROS-induced ROS release, a self-propagating phenomenon
in which ROS release from one mitochondrion could trigger
ROS release and depolarization of adjacent mitochondria in
a rapidly expanding pattern. The ability to propagate this
behavior was increased if glutathione levels were decreased.
Thus, it was recognized that under conditions of oxidative
stress a single damaged mitochondrion might be sufficient to
trigger a mitochondrial stampede to cell death.
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Ischemic preconditioning
The most potent and reproducible means to protect the
heart from ischemic injury is ischemic preconditioning
(IPC). In IPC, the heart is exposed to a brief ischemic stress
prior to the index ischemia. There is general agreement that
preconditioning converges on the mitochondria, triggering
mild depolarization, which is thought to prevent calcium
overload and mPTP opening. However, mild mitochondrial
depolarization is also known to trigger mitophagy: PINK1
is constitutively degraded so long as mitochondrial mem-
brane potential is high. However, when membrane poten-
tial drops, PINK1 accumulates and recruits Parkin, which
ubiquitinates multiple outer mitochondrial membrane pro-
teins and recruits the autophagic machinery.
Autophagy, which delivers cellular material to the lysosome
for degradation, was presumed to provide fuel for energy pro-
duction during ischemia; however, we now know that energy
production may not be critical. We have suggested that the value
of autophagy may lie in sequestering the most unstable mito-
chondria before they can set a stampede in motion. The evidence
for this is based on the report that preventing lysosomal degra-
dation does not affect infarct size in a Langendorff model of I/R
injury, and on the key observation that inactivation of Parkin-
dependent mitophagy abolishes ischemic preconditioning [1].
The study by Zoltan et al. showed that blocking initia-
tion of autophagy with a cell permeable dominant negative
Atg5 mutant (Tat-Atg5K130R) abolished the cardioprotec-
tive effects of the autophagy-inducing drug, chloram-
phenicol [2]. In contrast, blocking the degradative phase of
autophagy with the lysosomotropic agent chloroquine did
not interfere with cardioprotection mediated by chloram-
phenicol. This suggests that sequestration of material into
autophagosomes is essential for cardioprotection, but lib-
eration of breakdown products for energy production is not.
The study by Huang et al. showed that mitophagy
mediated by Parkin was essential for cardioprotection. In
that study, targets of autophagy—other than mitophagy—
were not disrupted but cardioprotection was lost. The most
reasonable interpretation (though not the only one) is that
provision of metabolites, which presumably was not
obstructed in the Parkin-null animals, was not as important
as sequestration of mitochondria, a process that depended
upon Parkin. This leads to the supposition that sequestra-
tion of damaged mitochondria will avert the propagation of
ROS-induced ROS release and cell death. Therefore, any
intervention that triggers mild mitochondrial depolarization
and removal by mitophagy could be cardioprotective.
Pharmacologic conditioning
Autophagy has been shown to be induced by a number of
cardioprotective agents, including diazoxide, UTP, CCPA,
ranolazine, rapamycin, sulfaphenazole, chloramphenicol,
and statins [3]. Not all of these agents have been evaluated
for their effects on mitochondrial membrane potential and
mitophagy, but a few have. Agents that are known to trigger
mild depolarization include those that open the mitochon-
drial ATP-sensitive potassium channel (mitoKATP), such as
diazoxide [4]; induction of uncoupling proteins [5–7];
volatile anesthetics, which act on BKCa [8]; low-dose FCCP
[9]; and interventions which trigger flickering of the mPTP
such as ischemic preconditioning [10]. These are all well-
known cardioprotective agents which additionally share the
property of causing mild mitochondrial depolarization. Not
all of these agents have been evaluated for their ability to
induce autophagy, but diazoxide and FCCP have been
shown to do so, and starvation-induced autophagy is
attenuated by inhibition or deletion of cyclophilin D, a key
regulator of the mPTP. None of these agents have been
assessed directly for their effects on Parkin translocation or
mitophagy, with the exception of FCCP and ischemic pre-
conditioning [1, 9]. Ischemic preconditioning triggered
rapid translocation of Parkin to mitochondria, followed by
mitophagy. Ischemic preconditioning was ineffective in
Parkin-null mice, implicating Parkin-dependent mitophagy
in the mechanism of cardioprotection.
The adaptive versus maladaptive story
Controversy exists as to whether autophagy is always a
good thing for the heart. Sadoshima’s group concluded that
autophagy was beneficial during ischemia but deleterious
during reperfusion [11]. However, they have not examined
ischemic preconditioning or other cardioprotective inter-
ventions. Bnip3, which is activated during ischemia/reper-
fusion, triggers mitochondrial depolarization and mitophagy
which is Parkin-dependent [12]. Bnip3, a pro-apoptotic
member of the Bcl-2 family, causes mitochondrial damage;
injury is exacerbated if autophagy is suppressed [13].
However, Beclin 1 haploinsufficiency was reported to
decrease ischemia/reperfusion injury, an effect which was
assumed to be due to diminished autophagy [11]. Partial
knockdown of Beclin 1 or haploinsufficiency does not limit
the initiation of autophagy, although a more complete
knockdown does [14]. Beclin 1 interacts with autophagy
machinery at the lysosomal fusion stage as well, and in that
setting, it delays autophagosome-lysosome fusion. Reduc-
tion in the amount of Beclin 1 actually accelerates flux,
resulting in fewer autophagosomes hanging around and the
misleading appearance of less autophagy.
This conundrum was beautifully elucidated recently by
Diwan’s group [15] and allows reinterpretation of the con-
fusing results of Hill’s group who reported that autophagy
contributed to maladaptive remodeling after severe TAC
[16]. They based their conclusions on the presence of
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increased number of autophagosomes after banding, which
was reduced in Beclin 1 haploinsufficient mice, and resulted
in a better outcome than WT mice. If Diwan’s study is cor-
rect, then we can reinterpret the observations of Zhu et al.
[16] to conclude that the increased autophagosome abun-
dance in the pressure-overloaded animals is a reflection of
compensatory autophagy that is somewhat ineffective due to
Beclin 1-mediated impairment of flux. Reducing Beclin 1
accelerates flux and ameliorates remodeling. This makes
sense for several reasons: (1) autophagy negatively regulates
cell size, so increased autophagy should oppose hypertrophy;
(2) autophagy is protective in other forms of heart disease
such as desmin-related cardiomyopathy (aggregopathy) and
ischemia/reperfusion injury; and (3) impaired autophagy is
associated with increased inflammation in a wide variety of
disorders, and inflammation contributes to most forms of
cardiac pathology.
Still to resolve are the findings from Sadoshima’s group
who have developed evidence that autophagy is beneficial
during ischemia but harmful during reperfusion [11, 17].
Although initial studies also relied on Beclin 1 (±) mice,
another study used AMPK-DN mice and reached similar
conclusions. It is possible that autophagy or mitophagy is
important for preconditioning or ischemia, but deleterious in
reperfusion. In contrast, chloramphenicol and sulfaphena-
zole, which are potent cardioprotectants effective when
given at reperfusion, act through induction of autophagy,
suggesting that autophagy is beneficial at reperfusion [3, 18,
19]. More work will be required to reconcile Sadoshima’s
findings and our own. While our studies have focused on
Parkin as an important mediator of mitophagy in IPC, it is
likely that it is not the only pathway. Degradation of indi-
vidual mitochondrial proteins via mitochondrial proteases or
the ubiquitin–proteasome system may proceed indepen-
dently of bulk degradation via mitophagy in steady state
conditions. Moreover, redistribution of mitochondrial pro-
teins via fusion and fission further complicates the analysis of
mitochondrial and protein turnover [20].
Is mitophagy enough?
One might wonder whether eliminating mitochondria is
such a good idea. After all, the heart needs lots of mito-
chondria to make ATP: can it afford to lose any? One
argument is that mitochondria which are damaged and
possibly uncoupled might actually consume ATP, so
eliminating those slackers might actually improve ATP
production efficiency. A second argument is that there may
be excess capacity. According to R. Balaban [21], in large
animals (dog, pig, human), ATP production in the resting
heart is about 20 % of maximal capacity; thus, loss of some
mitochondria will not limit cardiac ATP production until
demand is quite high. Note that in mice, basal cardiac ATP
production is already at 60 % of maximal capacity; thus, a
loss of mitochondria might affect cardiac function with just
a modest increase in work. The third and most appealing
argument is that mitochondrial biogenesis may be upreg-
ulated to keep up with destruction.
It is recognized that statins induce PGC1alpha, the
master regulator of mitochondrial biogenesis. Less is
known about whether other cardioprotective agents also
trigger biogenesis, but one hint is that a transcriptional
inhibitor of PGC1alpha, PARIS, is a substrate of Parkin
[22]. If PARIS spends time on mitochondria as well as in
the nucleus, then Parkin-dependent mitophagy would also
lower total levels of PARIS, leading to de-repression of
PGC1alpha and upregulation of mitochondrial biogenesis.
Finally, if mitophagy is too vigorous and ATP levels
decline, then AMP-activated kinase (AMPK) will activate
PGC1alpha. Thus, under normal conditions, homeostatic
mechanisms will preserve mitochondrial content. This may
be altered in type 2 diabetes mellitus (T2DM), where
autophagy is diminished, and where PGC1alpha is also
downregulated through modification of serine residues by
N-acetyl-glucosamine (O-GlcNAc) [23]. It is possible that
in this setting, if mitophagy is triggered, biogenesis may
not be upregulated appropriately. Conceivably, this loss of
homeostasis may demarcate the transition from compen-
sated heart failure to decompensation.
Efforts in the coming years should shed light on the
importance of homeostatic control of mitophagy and bio-
genesis. Even in settings where mitobiogenesis balances mi-
tophagy, the rate of turnover could contribute to
pathophysiology. Slow mitochondrial turnover may lead to
accumulation of damaged and inefficient mitochondria which
generate elevated levels of ROS, thereby driving inflamma-
tory signaling, as recently reported by two independent groups
[24, 25]. Otsu’s group showed that this contributed to adverse
cardiac remodeling [24]. Our understanding of mitochondrial
turnover will benefit from better tools to monitor the process.
These will likely come from proteomics in which isotopic
labeling will provide information about turnover of individual
proteins, and from use of transgenic mice that will allow
monitoring of mitochondrial turnover. Stay tuned for new
developments in this rapidly expanding field. Interestingly,
agents that accelerate mitochondrial turnover are all things we
consider ‘‘good for us’’, such as exercise, intermittent fasting
or caloric restriction, and statins, whereas things that suppress
autophagy (and mitophagy), including age, obesity, dyslipi-
demia, and insulin resistance, are associated with increased
risk of adverse cardiac outcomes.
Biogenesis, fission and fusion
Mitochondria are dynamic organelles—at least in cultured
cell lines—that interact as part of an interconnected
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network at some times and that exist as solitary organelles
at others. Key genes regulating mitochondrial dynamics
(fusion and fission) have been identified, and mutations are
associated with human disease, including Charcot-Marie-
Tooth type 2 (mitofusin2 mutation) and optic atrophy
(Opa1 mutation). Neither of these human mutations results
in clinically apparent heart disease, raising questions as to
the importance of mitochondrial fusion and fission in the
heart. However, conditional knockout of mitofusin1 and
mitofusin2 (mfn1/mfn2 DKO) results in development of
heart failure over several weeks, suggesting that mito-
chondrial fusion events are important to cardiac homeo-
stasis [26].
It appears that mitochondrial fusion events in the heart
occur on a glacial time scale, if at all. Dorn estimated that a
mitochondrial fusion/fission cycle in the heart occurs every
16 days. This is impossible to distinguish from mitochon-
drial turnover, as mitochondrial half-life in the heart is also
about 2 weeks. Interestingly, a recent paper by Zhao et al.
[27] proposes a role for Mfn2 in autophagosome/lysosome
fusion. It is possible that this second function of Mfn2 is
more important in the heart.
Finally, Scorrano has shown that Mfn2 is important for
anchoring specialized portions of the ER to mitochondria
[28]; this could be important for calcium regulation of
mitochondrial energetics; loss of Mfn2 anchoring could
lead to progressive derangement of calcium and energy
homeostasis. Moreover, Ngoh et al. [29] reported that
Mfn2 deletion amplified ER stress. Whether mitochondrial
fusion and fission events occur in the heart is a subject of
debate, as the tightly packed architecture of the cardio-
myocyte would pose considerable physical barriers. Dele-
tion of Mfn1 in the heart results in an increase in the
number of small spherical mitochondria and greater resis-
tance to hydrogen peroxide [30]. Deletion of both Mfn1
and Mfn2 results in cardiomyopathy and death by postnatal
day 16, [31] suggesting an important role for mitofusins
during early postnatal cardiac development.
Fusion/fission events are poorly understood in the con-
text of ischemic preconditioning or ischemia/reperfusion
injury. One study using mDivi1, an inhibitor of the fission
protein Drp1, concluded that inhibiting fission in the con-
text of I/R injury was protective [32]. However, further
evidence is needed to confirm that mDivi1 was acting
through inhibition of mitochondrial fission. The benefit of
acute administration of a fission inhibitor is inconsistent
with the exceedingly slow kinetics of fusion events in the
heart. Thus, it is likely that Drp1 has other functions (e.g.,
interaction with apoptosis machinery), mDivi1 has other
targets, or that fusion and fission events in the heart occur
much more rapidly under stress conditions. More work is
needed to understand the role of fission and fusion
machinery in the heart.
Autophagy and cardiac remodeling
Heart failure is a leading cause of death in the North
America and Europe. It is a clinical syndrome character-
ized by a decline in cardiac output, inadequate systemic
perfusion, and manifestations of pulmonary congestion and
peripheral vasoconstriction. Therapeutic interventions are
designed to improve contractility of the heart and reduce
peripheral arterial resistance. Despite the use of angiotensin
converting enzyme (ACE) inhibitors, beta blockers, vaso-
dilators, and diuretics, however, mortality remains high and
approaches 50 % at 5 years [33]. In order to develop more
effective therapies directed toward both prevention and
treatment, a much better understanding of the pathology
that leads to heart failure is needed.
The most commonly encountered pathologies that pro-
gress to heart failure are ischemic and load-induced
remodeling. Ischemic remodeling occurs after a myocardial
infarction; load-induced remodeling occurs in the setting of
hypertension (pressure overload), valvular dysfunction
(pressure or volume overload), and intrinsic contractile
abnormalities (certain cardiomyopathies). While both
involve multiple complex signaling pathways and neural-
humoral interactions, there is evidence that remodeling
also involves autophagy and mitophagy. It is controversial,
however, as to whether, in the context of remodeling, these
processes are adaptive or maladaptive.
Ischemic remodeling
The mechanisms involved in post-infarction cardiac
remodeling are multi-factorial and include neuro-humoral
imbalance, inflammation, and apoptosis [34]. It is defined
by infarct expansion and acute dilatation of the infarct
zone, dilatation of noninfarct zone and increased spheric-
ity, and ventricular hypertrophy. The end result is pro-
gressive deterioration in left ventricular function [35]. The
process is complicated, and many factors are associated
with disease progression including phosphoinositide-3-
kinase (PI3K), mitogen-activated protein kinase (MAPK)
pathways, altered extracellular matrix, and expression of
various cytokines, stress signaling, growth factors, fibrosis,
and myocyte loss. There is now evidence that autophagy
plays an important role as well [36–39].
Kanamori et al. [36, 40] used a mouse myocardial
infarction model to investigate the function of autophagy in
ischemic remodeling. The dynamics were assessed during
the subacute and chronic stages (1, 2 and 3 weeks) after
coronary occlusion. The effects of agents that alter the
autophagic process on the progression of post-infarction
remodeling and left ventricular function were studied as
well. These investigators observed an increase in auto-
phagic activity over time and a unique morphology and
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localization that was dependent on the stage of infarction.
During the subacute stage, autophagy was more prominent
in the border zone than in the more remote areas. In the
chronic stage, autophagic activity was greater in the remote
areas. The investigators speculate that the changing dis-
tribution of autophagic activity is related to the progression
of cardiac remodeling and are a reflection of changes in
wall stress. When bafilomycin A1 was used to block
autophagy, cardiac dysfunction was exacerbated; stimula-
tion of autophagy with rapamycin mitigated the cardiac
dysfunction and remodeling.
These findings are consistent with those reported by
Buss et al. [41, 42] who used a rat infarction model. In this
study, everolimus (RAD) was used to inhibit mTOR; RAD
treatment 1 day after the MI resulted in reduced ischemic
remodeling and improved LV function. The effects were
observed even when the animals were treated 3 days after
the MI. Sustained improvement of LV function was
observed 3 months after MI even when RAD treatment was
discontinued after 1 month. Collectively, these findings
and reports by others support the concept that autophagy is
an adaptive process that protects against adverse post-
ischemic remodeling.
Indirect evidence that autophagy plays a significant role
in protection against post-myocardial infarction remodel-
ing is found in preclinical studies examining the effects of
intermittent fasting (IF) and statins. After 3 months IF in
rats, Ahmet et al. [43, 44] induced MI in rats by permanent
coronary artery occlusion. In the IF cohort, infarct size
after 24 h was twofold smaller, the number of apoptotic
myocytes was fourfold less, and the inflammatory response
was reduced compared to rats with regular every day
feeding. Serial echocardiography that 10 weeks after MI
left ventricular (LV) remodeling and infarct expansion
were absent in the IF group. In a cohort of animals with
similar MI size at 1 week, there was less remodeling, better
LV function, and no MI expansion. They concluded that IF
protects the heart from ischemic injury and attenuates post-
MI cardiac remodeling through anti-apoptotic and anti-
inflammatory mechanisms. Although not emphasized by
this group, it is important to note that intermittent fasting
and caloric restriction (starvation) are potent inducers of
both autophagy and mitophagy.
With respect to statins, while 3-hydroxy-3-methylglut-
aryl coenzyme A (HMG-CoA) inhibitors are known to
reduce morbidity and mortality in patients with ischemic
heart disease, it is controversial whether they are effective
in reducing major cardiovascular events in patients with
established heart failure. In the CORONA and GISSI-HF
trials, rosuvastatin therapy (10 mg daily) was not associ-
ated with a reduction in major cardiovascular events [45,
46]. The findings strongly suggest that routine statin ther-
apy in heart failure patients is not warranted. It is important
to note, however, that (a) it is unknown whether higher
doses would have been beneficial and (b) in the CORONA
trial, statin therapy was associated with significantly fewer
hospitalizations. Interestingly, McMurray et al. [47], in a
retrospective study of the CORONA patients, reported that
rosuvastatin was associated with significantly better out-
comes in patients with hs-CRP C2.0 mg/L. Independent of
these findings, there is experimental evidence that statin
therapy may reverse pathologic ventricular modeling [48].
Hayashidani et al. [49] using a mouse myocardial
infarction model reported that fluvastatin, when added to
the drinking water for four weeks, increased survival from
61 to 86 %. Serial echocardiograms revealed a reduction in
chamber dilatation and hypertrophy and improvement in
ventricular function. Treatment was also associated with an
attenuation of the increase in metalloproteinases that was
observed in the untreated group. These observations are
consistent with and extend the findings by Lefer et al. [50]
who reported that statins are cardioprotective in the setting
of ischemia/reperfusion injury. Given the recent findings in
the Gottlieb laboratory [51] that statins exert their cardio-
protective properties through upregulation of autophagy
and mitophagy, it is possible that patients at risk of adverse
post-infarction remodeling might benefit from drugs that
target the machinery of autophagy and upregulate auto-
phagic flux.
In general, increasing cell size is mediated by mTOR,
which suppresses autophagy. In contrast, autophagy par-
ticipates in reducing cell mass and is generally considered
to be anti-hypertrophic. However, the energetic cost of
autophagy and the need to continually replace cellular
constituents may be too high a price to pay in a fragile,
energy-restricted heart. Thus, it is conceivable that
uncontrolled autophagy may contribute to the demise of
cells that are unable to counterbalance catabolism with
biosynthesis.
Load-induced remodeling
The initial response to pressure overload in the heart is an
increase in muscle mass to increase the force of contrac-
tion; the result is left ventricular hypertrophy. As with
ischemic remodeling, autophagy has been implicated in
playing an important role. There is, however, controversy
as to autophagic activation is beneficial or deleterious. To
investigate the role of autophagy, Zhu et al. [16] studied
mice subjected to surgical constriction of the proximal
aorta (severe thoracic aortic banding [sTAB]). At 24 h and
1 week, the mortality (\10 %) was comparable to con-
ventional thoracic aortic constriction (TAC) but function
indicators demonstrated a rapid onset of clinical heart
failure. The latter was associated with a marked increase in
the number of autophagosomes that peaked at 48 h and
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persisted for at least 3 weeks. In mice subjected to sTAB
that were haploinsufficient for Beclin 1, a protein required
for early autophagosome formation, autophagosome
abundance was blunted and pathologic remodeling was
diminished. Conversely, Beclin 1 overexpression increased
both autophagosome abundance and the severity of
remodeling. The investigators concluded that pressure
overload triggers cardiac autophagy, and this response
contributes to progression of heart failure. However, as
noted above, autophagosome abundance could be a sign of
impaired flux, which will increase inflammatory signaling
via the TLR9 and inflammasome pathways [22, 23].
In contrast, Nakai et al. [33] reported that activation of
autophagy is beneficial. Cardiac-specific deletion of Atg5, a
rate-limiting protein involved in autophagosome initiation,
resulted in cardiac hypertrophy, ventricular dilation, and
contractile dysfunction. Moreover, pressure overload in these
Atg5 mutant animals triggered a rapid and dramatic decline in
cardiac function. Ultrastructural analysis showed disorga-
nized sarcomere structure and mitochondrial misalignment
and aggregation. While cardiac-specific deficiency of Atg
early in cardiogenesis showed no such cardiac phenotypes
under baseline conditions, 1 week after TAC the animals
developed ventricular dysfunction and dilatation. The inves-
tigators concluded that basal autophagy is required for normal
cardiac function and upregulation of autophagy is an adaptive
response to hemodynamic stress. Similar findings have been
reported by other investigators, albeit more indirectly [39].
The inconsistent conclusions regarding the role of
autophagy in overload remodeling is related to the model
studied. Rothermel and Hill [52] have suggested that Atg5
deficient mice have near-complete loss of constitutive
autophagy while the Beclin 1 ?/- mice have only a 50 %
reduction. As a consequence, functions carried out by basal
levels of autophagy are lost in the Atg5-deficient hearts but
not in the Beclin 1 ?/- hearts. They suggest that this
explains why WT mice, in the setting of pressure overload,
are able to mount a robust autophagic response that is
maladaptive. A more likely explanation, however, rests
with the findings by Ma et al. [15] discussed earlier in the
section on cardioprotection, namely, that Beclin 1 inhibits
autophagic flux: (a) with less clearance there is less pro-
tection against remodeling, (b) in the Beclin 1 ?/- mice,
there is less inhibition of autophagic flux; hence, there is
less adverse remodeling. If the findings by Diwan’s group
are confirmed by other laboratories, then these two seem-
ingly contradictory observations can be reconciled without
having to implicate a threshold for autophagy, whereby it is
adaptive in the same setting under one set of conditions and
maladaptive in another. If autophagy is indeed principally
an adaptive process, this would suggest that maladaptive
autophagy is more likely a reflection of dysfunctional
autophagy.
Indirect evidence that autophagy plays a role in moder-
ating hypertrophy is the study by Finckenberg et al. To
evaluate the role of caloric restriction (CR), this group used
4-week-old double transgenic rats (dTGR) with human
renin and angiotensinogen genes. The objective was to test
the hypothesis that CR would have a salutary effect on
survival. In the CR animals, angiotensin II (Ang II)-induced
mitochondrial remodeling and cardiac hypertrophy via
blood pressure-independent mechanisms were ameliorated.
These changes were associated with increased endoplasmic
reticulum stress signaling and autophagy. The end result
was superior survival; the mortality was 85 % in the unre-
stricted diet dTGRs and 25 % in the CR cohort at 8 weeks.
The investigators concluded that CR, in this setting, affords
protection against cardiac hypertrophy and death. However,
CR may confer other benefits independent of autophagy.
In summary, the role of autophagy in the modulation of
load-induced remodeling is controversial. The issue, how-
ever, is not whether it is important, but rather whether
activation of the autophagic machinery is beneficial or
deleterious. Independent of the controversy, it appears that
sufficient evidence is available to warrant the development
of pharmacological agents that are designed to target the
autophagy process in an effort to prevent and treat load-
induced adverse remodeling.
Desmin-related cardiomyopathy (DRCM)
DRCM is a cardiomyopathy caused by a missense mutation
in the aB-crystallin (CryAB) gene and is characterized by
accumulation of misfolded proteins. To assess whether
accumulation of aggregate-prone protein affects autophagic
activity, Tannous et al. [53] infected neonatal rat ventricular
myocytes (NRVMs) with virus containing WT human
CryAB (Ad-CryABWT), virus expressing mutant human
CryABR120G or empty virus. Mutant CryABR120G triggered
a[twofold increase in autophagic activity. Overexpression
of CryABR120G induced aggregate accumulation and sys-
tolic heart failure. Autophagic activity was detected at
2 months well before there was evidence of a decline in
cardiac function which was evident at 12 months. When
CryABR120G mice were crossed with Beclin 1 ?/- mice,
autophagy was blunted and heart failure progression
increased. This was associated with an acceleration of
ventricular dysfunction and early mortality. These findings
suggest that activation of autophagy in this setting is ben-
eficial in attenuating progression of protein misfolding
cardiomyopathies.
Lysosomal storage diseases
Danon disease is a glycogen storage disease that may
present as a cardiomyopathy. It is characterized by
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defective autophagosome-lysosome fusion due to a muta-
tion in the lysosomal membrane receptor LAMP2 (lyso-
some-associated membrane protein 2). Deficiency of this
autophagy gene results cardiomyopathy, myopathy, and
variable intellectual disability; pathologically the patients
have intracytoplasmic vacuoles containing autophagic
material and glycogen in skeletal and cardiac muscle cells.
The accumulation of autophagosomes in this glycogen
storage disease is consistent with a defect in autophago-
some clearance, that is, impairment in autophagic flux.
Given that impaired autophagic clearance is a hallmark of
the disease, a therapeutic approach might be the use of
pharmacological agents to inhibit the initiation of autoph-
agy in order to reduce the autophagosomal burden [54].
Fabry disease is a lysosomal storage disorder caused by
a deficiency in a-galactosidase A that results in progressive
accumulation of neutral glycosphingolipids. It is associated
with hypertrophic cardiomyopathy that is responsive to
enzyme replacement therapy [55]. Recently, Fabry cells
were shown to exhibit impaired autophagic flux [56].
Pompe disease, is a lysosomal storage disorder caused by
deficiency of acid alphaglucosidase, resulting in massive
accumulation of glycogen in cardiac and skeletal muscle,
leading to progressive dysfunction. Enzyme replacement is
more effective for ameliorating cardiac hypertrophy than
for skeletal muscle. Recently, it was reported that sup-
pressing autophagy improved the efficacy of enzyme
replacement in a mouse model of the disorder [57].
What these diseases of lysosomal function reveal is that
impaired autophagic flux is as bad (and perhaps worse) for
the heart as insufficient autophagy. Lysosomal storage
diseases, in which the dominant feature is accumulation of
glycogen or glycosphingolipids, may carry a second mode
of injury in which degradation of other cellular constituents
(such as mitochondria) may lead to activation of inflam-
matory pathways. The severe consequences of pressure
overload in mice lacking the lysosomal enzyme DNase II,
required to degrade mitochondrial DNA [24], illustrate the
inflammatory consequences of lysosomal dysfunction
leading to interaction of nondegraded mitochondrial DNA
with TLR9 or the inflammasome.
Autophagy and heart failure
In contrast to remodeling, the role of autophagy in heart
failure is less clear. While autophagic activation may
protect the heart from failing, there are reports that
autophagy is associated with the progressive destruction
of cardiomyocytes in the failing heart; the implication
being that autophagy causes failure. Shimomura et al.
[58] examined heart tissue resected during partial left
ventriculectomy in 27 patients with idiopathic dilated
cardiomyopathy. Electron microscopy revealed degener-
ated mitochondria and myofibrillar lysis. Large vacuoles
were surrounded by a single membrane and occasionally
contained intracytoplasmic organelles which suggested that
they were autophagic vacuoles. On the basis of these
findings, it was suggested that autophagic degeneration
may represent one of the underlying mechanisms of heart
failure. What was not addressed was the presence or
absence of double membrane structures so characteristic of
viable autophagosomes.
To explore this possibility, Miyata et al. [59] studied the
UM-X7.1 hamster model of human dilated cardiomyopa-
thy. In this model, heart failure develops progressively and
the mortality rate is 50 % at 30 weeks of age. Ultrastruc-
tural analysis of these hearts revealed that many of the
cardiomyocytes contained autophagy vacuoles and degra-
ded mitochondria. Immunoassays showed that most of the
cardiomyocytes with a leaky plasma membrane were
positive for cathepsin D. Based on these findings, it was
concluded that there is a causative link between autophagic
activity and cell death. In a separate series of experiments,
UM-X7.1 hamsters were treated with granulocyte colony-
stimulating factor (GCSF). The rational was based on
reports that GCSF is a regeneration- and/or repair-related
cytokine. Treatment resulted in a marked improvement in
survival, ventricular function, and remodeling. This paral-
leled a reduction in myocardial fibrosis and autophagy.
Since there was no evidence of transdifferentiation from
bone marrow cells into cardiomyocytes, it was concluded
that the beneficial effects of GCSF were due to an anti-
autophagic mechanism.
This study is similar to other studies that rely primarily
on electron microscopy to establish a link, positively or
negatively, between autophagic activity and myocardial
remodeling. Ultrastructural analyses cannot ascertain
whether the presence of autophagosomes reflect a cause of
injury or, in fact, represent a targeted response to injury.
And, as noted earlier, autophagic flux needs to be taken
into account. In the absence of flux measurements, one
could mistakenly conclude that autophagy is the cause of
heart failure in Danon disease as opposed to impaired
autophagy.
An intriguing report by Kassiotis et al. [38] supports the
view that autophagy is an adaptive mechanism in the
failing human heart. They studied tissue samples from 9
patients diagnosed with dilated cardiomyopathy who were
placed on a left ventricular assist device for end stage heart
disease. Left ventricular tissue was obtained from the apex
during implantation of the device and upon explantation of
the device at the time of transplantation. To determine how
levels of autophagy were influenced by mechanical
unloading, autophagy markers were measured prior to and
following unloading. In the unloaded failing heart, the
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Atg5-Atg12 conjugate, Beclin 1, and LC3-II were all
decreased. Because a number of signaling pathways that
that regulate both autophagy and apoptosis overlap, apop-
totic markers were also assessed pre- and post-mechanical
unloading [60]. In this study, there was no significant dif-
ference in Bcl-2 levels or TUNEL-positive nuclei between
groups. Although the effect of unloading on apoptosis was
unclear, the investigators concluded that mechanical
unloading decreases autophagy and autophagy is an adap-
tive mechanism in the failing heart.
Conclusion
Autophagy and mitophagy play an important role in the
modulation of ischemia–reperfusion injury, remodeling,
and heart failure. While controversy exists as to whether
this is a salutary or deleterious role, the preponderance of
evidence suggests that autophagy and mitophagy are
important protective mechanisms across the spectrum of
ischemic injury. Autophagy is a means to de-clutter the cell
and restore functionality (Fig. 1). It is likely that dys-
functional or impaired autophagy contributes to the mor-
bidity and mortality associated with cardiovascular disease.
For autophagy to move fully into the therapeutic arena,
however, better tools are needed to facilitate the discrimi-
nation between functional autophagy and dysfunctional
and/or impaired autophagy, as well as to image autophagy
in vivo. Likewise, a better understanding of the function-
ality of autophagy and interplay between mitophagy and
mitochondrial biogenesis is needed. Both could open the
door to the development of novel effective therapies for the
prevention and treatment of ischemia–reperfusion injury,
pathological remodeling, and heart failure in humans.
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